Aeolus Pharmaceuticals (AOLS) Stock Price, News & Analysis

Company Overview

Aeolus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of fibrotic and inflammatory diseases. The company’s research and development efforts are centered on small-molecule and biologic candidates designed to modulate key pathways involved in tissue scarring and immune response. Aeolus aims to address unmet medical needs in conditions such as idiopathic pulmonary fibrosis, liver fibrosis and acute lung injury by advancing compounds from discovery through clinical trials.

The company’s lead programs include several preclinical and early clinical candidates targeting fibrosis and inflammation. One of its flagship assets is AEL-101, an oral small molecule inhibitor of the transforming growth factor-beta (TGF-β) signaling pathway, which plays a critical role in fibroblast activation and extracellular matrix deposition. In addition, Aeolus is advancing AEL-201, a monoclonal antibody aimed at neutralizing pro-inflammatory cytokines implicated in acute respiratory distress syndrome. These programs underscore Aeolus’s approach of combining molecular biology insights with rigorous translational research to create differentiated therapies.

Aeolus Pharmaceuticals was founded in 2015 and is headquartered in Irvine, California, with additional research operations in Boston, Massachusetts. The company’s scientific teams engage in collaborative partnerships with academic institutions and contract research organizations across North America and Europe to support preclinical studies and clinical trial execution. By leveraging these alliances, Aeolus ensures access to state-of-the-art technologies and patient populations needed to validate its therapeutic platforms.

Leadership at Aeolus is led by Chief Executive Officer Gary Strumwasser, who brings over two decades of experience in pharmaceutical development and biotechnology commercialization. He is supported by a seasoned management team with backgrounds in clinical operations, regulatory affairs and medicinal chemistry. Guided by a mission to improve outcomes for patients living with debilitating fibrotic diseases, the company continues to expand its pipeline and pursue strategic collaborations to accelerate the delivery of new treatments to market.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0050
• Volume: 1,940 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AOLS Stock Analysis - Frequently Asked Questions

How have AOLS shares performed this year?

Aeolus Pharmaceuticals' stock was trading at $0.0003 at the start of the year. Since then, AOLS shares have decreased by 66.7% and is now trading at $0.0001.

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) released its earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter.

How do I buy shares of Aeolus Pharmaceuticals?

Shares of AOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aeolus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeolus Pharmaceuticals investors own include Myriad Genetics (MYGN), Nutra Pharma (NPHC), Synergy Pharmaceuticals (SGYP), Titan Pharmaceuticals (TTNP), ADOMANI (ADOM), Agritek (AGTK) and Akers Biosciences (AKER).

Company Calendar

• Last Earnings: 8/14/2017
• Today: 7/23/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AOLS
• CIK: 1261734
• Web: www.aeoluspharma.com
• Phone: (949) 481-9825
• Fax: 949-481-9829
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.28